The transforming growth factor-b (TGF-b) superfamily has essential roles in lung development, regulating cell proliferation, branching morphogenesis, differentiation and apoptosis. Although most lung cancers become resistant to the tumor suppressor effects of TGF-b, and loss or mutation of one of the components of the TGF-b signaling pathway, including TbRII, Smad2 and Smad4 have been reported, mutations are not common in non-small cell lung cancer (NSCLC). Here we demonstrate that the TGF-b superfamily co-receptor, the type III TGF-b receptor (TbRIII or betaglycan) is lost in the majority of NSCLC specimens at the mRNA and protein levels, with loss correlating with increased tumor grade and disease progression. Loss of heterozygosity at the TGFBR3 genomic locus occurs in 38.5% of NSCLC specimens and correlates with decreased TbRIII expression, suggesting loss of heterozygosity as one mechanism for TbRIII loss. In the H460 cell model of NSCLC, restoring TbRIII expression decreased colony formation in soft agar. In the A549 cell model of NSCLC, restoring TbRIII expression significantly decreased cellular migration and invasion through Matrigel, in the presence and absence of TGF-b1, and decreased tumorigenicity in vivo. In a reciprocal manner, shRNA-mediated silencing of endogenous TbRIII expression enhanced invasion through Matrigel. Mechanistically, TbRIII functions, at least in part, through undergoing ectodomain shedding, generating soluble TbRIII, which is able to inhibit cellular invasiveness. Taken together, these results support TbRIII as a novel tumor suppressor gene that is commonly lost in NSCLC resulting in a functional increase in cellular migration, invasion and anchorageindependent growth of lung cancer cells.
Introduction
The transforming growth factor-b (TGF-b) superfamily is composed of .30 polypeptide growth factors that regulate essential processes including cell proliferation, differentiation, adhesion, angiogenesis and embryonic development (1) (2) (3) (4) (5) . Three highly conserved and tissue-specific TGF-b isoforms signal through heteromeric complexes of three cell-surface receptors, the type III TGF-b receptor (TbRIII or betaglycan), the type II TGF-b receptor (TbRII) and the type I TGF-b receptor (TbRI). Upon ligand binding, the constitutively active TbRII transphosphorylates the GS region of TbRI to activate its kinase function. TbRI can then phosphorylate C-terminal serine residues on transcription factors known as Smads, specifically the receptor Smads, Smad2 and Smad3, which then associates with the common Smad, Smad4. This association allows translocation of the complex into the nucleus and transcription of target genes. This classical Smaddependent TGF-b signaling results in negative regulation of cell proliferation in epithelial, endothelial and hematopoietic cells (1, 6) . TbRIII, the most abundantly expressed TGF-b receptor, is an 849 amino acid heparan sulfate proteoglycan with a short cytoplasmic tail that fundamentally contributes to TGF-b signaling, resulting in either inhibition or enhancement of signaling, through mechanisms yet to be defined (2, 7, 8) . TbRIII is classically thought to function as a TGF-b superfamily co-receptor, presenting ligand to the signaling receptors (9) . Recent studies have suggested an essential, non-redundant role for TbRIII in mediating and regulating signaling through TbRII and TbRI as well as potentially signaling independently of TbRII and TbRI. Importantly, TbRIII null embryos are not viable and die between embryonic day 16.5 and birth with hepatic and cardiovascular defects (10) . An essential role for TbRIII has also been demonstrated in mesenchymal transformation in chick embryonic heart development (11, 12) and in mediating TGF-b resistance in intestinal goblet cells (13) . We have defined essential roles for the cytoplasmic domain of TbRIII in mediating TGF-b signaling independent of the ligand presentation role (11) , along with regulating cell-surface levels of TbRIII and TbRII through interactions with GAIP-interacting protein, C terminus (GIPC) (14) and b-arrestin2 (11) .
The TGF-b signaling pathway has an essential role in lung development through its regulation of angiogenesis, proliferation and differentiation (15) . Although many lung cancers become resistant to the homeostatic effects of TGF-b, the mechanism by which this occurs is not known. Loss or mutation of one of the components of the TGF-b signaling pathway, including TbRII, Smad2 and Smad4 have been reported previously; however, these mutations are not common in non-small cell lung cancer (NSCLC) (16) . Smad2 and Smad4 mutations have been found in only 5-10% of lung cancers and most NSCLC express both TbRI and TbRII (17) (18) (19) . Given that the expression and functional significance of TbRIII in lung cancer have not been established and that TbRIII has an emerging role in regulating TGF-b signaling, here we investigate the role of TbRIII in NSCLC.
Materials and methods
cDNA array A filter array containing normalized cDNA from 21 lung cancers and corresponding normal tissues (Cancer Profiling Array I, Clontech, Mountain View, CA) was probed with [ 32 P]-labeled cDNA probes for TbRIII following methods recommended by the manufacturer. In the 21 lung cancer samples, there were 11 squamous cell, 5 adenocarcinoma (one including squamous cell features), 3 bronchioloalveolar adenocarcinoma and 2 malignant carcinoid tumors. The TbRIII cDNA probe was polymerase chain reaction (PCR) amplified using the forward primer, gtagtgggttggccagatggt, and reverse primer, ctgctgtctcccctgtgtg. Purified PCR products (25 ng) were labeled by randomprimed DNA labeling using [ 32 P]-dCTP following the manufacturer's protocol (Roche Molecular Biochemicals, Indianapolis, IN). Labeled cDNA probe was purified on BD CHROMA SPINþSTE-100 column (BD Bioscience Clontech, Mountain View, CA). Images were acquired using a phosphorimager, and subsequent data analysis was performed using NIH Image J software. The densitometry units for the TbRIII probed array (with background subtracted) were normalized to densitometry units for a control ubiquitin probed array (with background subtracted). A ratio (normal/tumor) of 1.8 or higher was considered significant.
DNA extraction and microsatellite-PCR loss of heterozygosity analysis
Fifteen patients' lung tumor samples along with patient-matched normal lung tissues (paraffin embedded) were obtained from the DUKE Cancer Tissue Bank. DNA was extracted as previously described (20) . Microsatellite markers, D1S1588, D1S188 and D1S2804, in which the forward primer was synthesized with a 5# fluorescent tag (Integrated DNA Technology), were used in PCRs with the genomic DNA and analyzed for loss of heterozygosity (LOH) by sequencing and analysis on high melting temperature agarose gels, as described previously (20) .
Cell culture and reagents A549 and H460 cells were generously provided by Dr Michael Kelley's Laboratory (Duke University). Both cell types were maintained in RPMI 1640 media supplemented with 10% fetal bovine serum (FBS). Cells were passaged at 37°C in 5% CO 2 .
Stable cell lines
Using two 10 cm plates per cell type, A549 and H460 cells were plated in RPMI 1640 media supplemented with 10% FBS and grown to 80% confluency in each dish. In one 10 cm plate, 10 lg full-length, HA-tagged human TbRIII was transfected using Fugene according to the manufacturer's protocol. The empty vector pcDNA3.1 was transfected in the other dish following the same transfection protocol. After 48 h, selection was performed as described previously (20) .
Monolayer wound healing, fibronectin transwell and Matrigel invasion assays Performed as described previously, with the exception of 20 000-25 000 A549 cells stably expressing pcDNA3.1 or TbRIII utilized for fibronection transwell motility assays and 50 000-100 000 cells of A549 stable cells lines for Matrigel invasion assays (20) . Experiments requiring adenovirus infection utilized A549-Neo cells initially plated in six-well dishes and infected with shTbRIII or shEND (control) 48-72 h prior to plating on Matrigel filters. Knockdown of TbRIII expression was confirmed at these time points by 125 I-TGF-b1 binding and cross-linking.
Colony formation in soft agar
The 12-or 24-well plates were coated with a 1.6% agarose, 2Â Dulbecco's modified Eagle's medium and FBS solution and allowed to solidify to form the base agar with a final concentration of 0.71% agarose. H460 cells were counted and 1 Â 10 4 or 1 Â 10 5 cells (per triplicate) were added to a master mix containing 2Â Dulbecco's modified Eagle's medium, 1% agarose, FBS and RPMI (containing 10% serum and 500 lg/ml G418) with the final top agar concentration of 0.4% agarose. The plates were put at 4°C for 10 min to solidify the top agar and then incubated at 37°C in 5% CO 2 for 7 to 14 days. Cells were examined with a Â4 objective and also stained with a 0.02% crystal violet solution overnight and colonies were counted using Adobe Photoshop.
Tumorigenicity in nude mice
A total of 200 000 A549-Neo or A549-RIII cells were suspended in 100 ll sterile phosphate-buffered saline and injected subcutaneously into both flanks of 4-to 6-week-old female Balb/cAnNcr-Nu/Nu mice (NCI-Frederick). The A549-Neo group was composed of six mice and the A549-RIII group was composed of seven mice. Tumor volume was measured every 3 days in two dimensions using calipers. Tumor volume was determined using the following formula:
, where L represents the larger dimension and W the smaller dimension. Weight of the mice was also monitored every 3 days.
Results

Loss of TbRIII expression in NSCLC
To investigate whether TbRIII expression was altered in NSCLC specimens, we initially analyzed a cDNA array containing 21 human NSCLC samples with matched normal controls ( Figure 1A) . Across all specimens, we observed a 2.4-fold decrease in TbRIII mRNA expression in tumor versus normal samples (P , 0.01, two-tailed t-test) ( Figure 1B) . TbRIII mRNA expression levels were reduced in 66.7% (14/21) of the NSCLC samples, including in 80% (4/5) of the adenocarcinoma specimens, 100% (3/3) of the bronchioalveolar adenocarcinoma specimens, 54.5% (6/11) of the squamous cell carcinoma specimens and 50% (1/2) of the malignant carcinoid specimens ( Figure 1C ). To confirm decreased expression of TbRIII in these subtypes of NSCLC, we examined expression at the protein level by performing immunohistochemical analysis for TbRIII protein expression on a commercially available lung cancer tissue array containing 56 cases of NSCLC tumor along with matched normal lung tissue. TbRIII staining intensity for each core lung tissue sample was scored on scale of 0-4 by three independent observers, including a board certified pathologist, where a score of 0 corresponds to no staining, 1 to trace staining, 2 to low levels, 3 to medium levels and 4 to high levels of specific staining ( Figure 2A ). Overall, there was a significant decrease in TbRIII staining in the tumor tissues (N 5 46) compared with normal tissues (N 5 29) ( Figure 2B , P , 0.0001, two-tailed t-test). When broken down by histological subtype, there was also a significant decrease in TbRIII staining in adenocarcinoma specimens (n 5 18) compared with normal tissues ( Figure 2B , P 5 0.017, two-tailed t-test) and in squamous cell carcinoma specimens (n 5 26) compared with normal tissues ( Figure 2B , P , 0.0001, twotailed t-test). Further analysis of the squamous cell carcinoma specimens demonstrated a significant decrease in TbRIII expression with increasing tumor grade ( Figure 2C , P , 0.001, analysis of variance). To directly assess the role of loss of TbRIII expression in NSCLC TbRIII suppresses lung cancer invasiveness progression, we assessed matched tissue sets for which matching normal lung and NSCLC specimens were available for analysis ( Figure 2D ). The majority of matched pairs that had specific staining (74%, 17/23) demonstrated a change in TbRIII expression, with a decrease in 88% (15/17) of the pairs ( Figure 2D ).
As TbRIII protein levels correlated with the TbRIII mRNA levels, we examined publicly available databases for additional confirmation of loss of TbRIII expression in NSCLC specimens. Using four previously published gene profiling studies of benign lung and lung cancer specimens publicly available through the Gene Expression Omnibus repository and the Oncomine Gene Profiling Databases (www.oncomine.org), we established that mean TbRIII mRNA levels were decreased in adenocarcinoma lung tumor tissue as compared with normal lung tissue in all four studies (Supplementary Figure 1A available at Carcinogenesis Online) (21) (22) (23) (24) . Moreover, combining all four studies in a meta-analysis, we calculated the combined standard difference in means to be À1.58 ± 0.183 (95% confidence interval À1.94 to À1.22, P , 0.0001, Supplementary Figure 1B available at Carcinogenesis Online), confirming loss of TbRIII expression in adenocarcinoma as compared with benign lung. There was a similar statistically significant decrease in TbRIII mRNA levels in squamous cell carcinoma samples relative to normal controls (data not shown). In two of the four studies, TbRIII expression was also available for well versus poorly differentiated tumors. A meta-analysis of these two studies revealed decreased TbRIII expression in poorly differentiated lung cancers relative to well-differentiated lung cancers, with a standard difference in means of À1.09 ± 0.31 (95% confidence interval À1.69 to À0.49, P , 0.0001, Supplementary Figure 1C available at Carcinogenesis Online). One additional study by Raponi et al. (25) demonstrated a trend (P 5 0.056) toward decreased TbRIII expression with decreased squamous cell carcinoma patients' 5-year survival. Taken together, these results support decreased TbRIII expression in NSCLC at both the message and protein level, with decreased expression correlating with NSCLC progression and increasing tumor grade, and a trend towards decreased survival.
Loss of heterozygosity at the TGFBR3 genomic locus The short arm of chromosome 1, where TGFBR3 is located, exhibits loss of heterozygosity in a number of human cancers, including lung cancer (26) . Here, we explored whether LOH represents a mechanism for decreased TbRIII expression in human lung cancer. We first performed PCR-based LOH analysis using three microsatellite markers (D1S1588, D1S188 and D1S2804) that are informative for the TGFBR3 genomic locus at 1p32 on 15 NSCLC patients' tumormatched normal tissue specimens. Using these three markers (informative for 13/15 samples) in two experimental methods (sequencing and PCR gel analysis), we established that 38.5% (5/13) of our samples displayed LOH at the TGFBR3 genomic locus ( Figure 3A , data not shown). To establish whether LOH correlated with loss of TbRIII expression at the protein level, we examined TbRIII expression by immunohistochemistry on these tissues and confirmed that a decrease in TbRIII protein expression correlated with LOH at the TGFBR3 genomic locus in every sample (5/5, Figure 3B and C; the colour version of Figure 3 is available at Carcinogenesis Online). In addition, the other eight tumor samples demonstrated a decrease in TbRIII protein expression compared with their matched normal counterparts, suggesting there could be other methods for this loss, including epigenetic regulation, which we have previously demonstrated in breast and prostate cancer (20, 27) .
TbRIII expression does not affect lung cancer cell proliferation
To examine the effects of altered TbRIII expression on NSCLC cells, we initially screened a number of NSCLC cell lines for TGF-b responsiveness and TGF-b receptor levels. We chose to focus on two adherent NSCLC cell lines, A549 and H460, which are commonly used and express relatively normal levels of TbRII and TbRI, but low to normal levels of TbRIII. We then created stable cell lines for both A549 and H460 expressing TbRIII (A549-RIII, H460-RIII) and control cell lines expressing empty vector, pcDNA3. Figure 2B available at Carcinogenesis Online). We then characterized the effect of TbRIII on TGF-b1-mediated inhibition of growth, which assessed the combined effects on proliferation and apoptosis. Exogenous expression of TbRIII had no effect on A549 cell growth in the presence or absence of 100 pM TGF-b1, as the growth curves of A549-Neo and A549-RIII were similar and within error, with or without TGF-b1 treatment (Supplementary Figure 2C available at Carcinogenesis Online). Similar results were seen in the H460 stable cell lines, with 100 pM TGFb1 having no significant affect on H460-Neo versus H460-RIII growth curves (Supplementary Figure 2C available at Carcinogenesis Online). To confirm TGF-b responsiveness in our cell lines, as has been demonstrated previously for the A549 cells (28, 29) , a dose response of TGF-b1 treatment was performed and Smad2 and Smad3 phosphorylation were examined. The results demonstrate that both cell lines are TGF-b1 responsive, and that although TbRIII expression slightly increased Smad2 phosphorylation in A549 cells, overall their ability to phosphorylate Smad2 or Smad3 was not significantly changed (Supplementary Figure 3A available at Carcinogenesis Online). In addition, a luciferase assay using Smad-responsive reporters (3TP and pE2.1) confirmed that all stable cells were TGF-b1 responsive, with TbRIII expression having modest but opposing effects on these reporters in the A549 cell line (Supplementary Figure 3B available at Carcinogenesis Online). Taken together, these results demonstrate that TbRIII expression had no significant effect on cell growth in vitro and did not significantly alter TGF-b1-dependent Smad phosphorylation or TGF-b1 responsiveness in the A549 or H460 stable cell lines.
TbRIII inhibits lung cancer cell motility
As our expression analysis demonstrated a decrease in TbRIII expression in NSCLC relative to benign lung, and in poorly differentiated/ high-grade tumors relative to well-differentiated/low-grade tumors, we investigated whether TbRIII has a role in regulating cell migration and/or invasion. A monolayer wound healing assay was first used to explore the role of TbRIII in regulating cell migration (30) . H460 cells form poor monolayers and migrate quite slowly, whereas A549 cells form robust monolayers, leading us to examine A549 lung cancer cells in this assay. Over a 24 h time course, A549 cells stably expressing TbRIII consistently migrated at a slower rate than empty vector control A549-Neo cells ( Figure 4A and B) . After 24 h, wounds in confluent A549-Neo cells were 90% closed, whereas wounds in confluent A549-RIII cells were 65% closed (P 5 0.035, two-tailed t-test) ( Figure 4A and B) .
Although results from the monolayer wound healing assay suggested that expression of TbRIII was sufficient to inhibit cellular migration, to further establish a role for TbRIII in inhibiting cellular migration we examined cell migration in fibronectin-coated transwells seeded with either A549-RIII or control A549-Neo cells, with or without the addition of TGF-b1. Again, A549-RIII cells were impaired in their ability to migrate relative to A549-Neo cells, with 67 ± 0.4% of the A549-RIII cells migrating at 24 h relative to the A549-Neo cells (P , 0.0001, two-tailed t-test) (Figure 4C and D) . The addition of 150 pM TGF-b1 had only minimal effects on the migration of the A549 stable cells. Notably, as established by our growth curves, these differences were not due to variances in cell growth at this time point (Supplementary Figure 2C available at Carcinogenesis Online). Collectively, these results confirm a role for TbRIII in reducing lung cancer cellular motility in vitro.
TbRIII inhibits lung cancer cell invasion through Matrigel through generation of sTbRIII Two necessary components for lung cancer metastasis are increased motility along with increased invasion through the basement membrane. We used the reconstituted extracellular matrix, Matrigel, to mimic the basement membrane and examined the role of TbRIII on lung cancer cell invasion through Matrigel in vitro (31). Stable expression of TbRIII in A549 lung cancer cells significantly inhibited Fig. 3 . Loss of heterozygosity of the TGFBR3 genomic locus correlates with decreased expression in NSCLC. (A) Genomic DNA was extracted from 15 patient tumor-matched normal lung tissue samples to examine the TGFBR3 locus through PCR-based LOH analysis using three microsatellite markers, with these PCR products analyzed using an ABI sequencer. Graphically represented are a matched normal (top)/tumor (bottom) sample, from which peak areas were determined and an LOH ratio was ascertained, demonstrating LOH of the TGFBR3 locus on chromosome 1p32 in the tumor sample. (B-C) Loss of TbRIII protein expression in the tissue specimens exhibiting LOH at the TGFBR3 genomic locus was confirmed by immunohistochemistry, with high TbRIII expression in normal lung tissue (B), and loss of expression in the corresponding NSCLC specimen (C), indicated by arrows.
TbRIII suppresses lung cancer invasiveness their ability to invade Matrigel by 71 ± 10% (P , 0.001, two-tailed t-test) ( Figure 5A ). Although the addition of 150 pM TGF-b1 increased invasion of A549-Neo cells by an average of 18% and A549-RIII cells by 30% compared with the same cell lines without TGF-b1 treatment, in both cases, TbRIII was able to decrease invasiveness (P 5 0.0172, Kruskal-Wallis test) ( Figure 5B ).
Although the ability of exogenous TbRIII to decrease both basal and TGF-b-stimulated invasion suggested a role for TbRIII in regulating invasion, to provide direct evidence for a role of TbRIII, we utilized shRNA-mediated silencing of endogenous TbRIII expression. In A549 cells, shRNA to TbRIII specifically knocked down TbRIII expression by 72%, as determined by densitometry of TbRIII crosslinked to iodinated TGF-b1, normalized to b-actin, relative to A549 cells infected with control shRNA to the related TGF-b co-receptor endoglin (shEND, Figure 5C ). This knockdown in endogenous TbRIII expression resulted in enhanced Matrigel invasion with a 2.2 ± 0.5 fold increase in invasion compared with shEND (control) infection (P 5 0.04, one-tailed t-test, Figure 5C ). These results support a direct role for TbRIII in regulating cellular invasion.
TbRIII undergoes proteolytic cleavage in the extracellular domain generating soluble TbRIII (sTbRIII), which has been demonstrated to suppress tumor growth (32) . Accordingly, to assess whether the effects of TbRIII were mediated by the production of sTbRIII, we first examined whether the A549-RIII cell line produced sTbRIII. Conditioned media from the A549-RIII and A549-Neo cell lines were cross-linked with iodinated TGF-b1 and sTbRIII was specifically immunoprecipitated with an antibody to the extracellular domain. These studies determined that both the A549-RIII and A549-Neo cell lines produced sTbRIII, with the A549-RIII cell line producing more than the A549-Neo cell line, as expected ( Figure 5D ). We then examined the effect of sTbRIII on A549 lung cancer cell invasion in vitro. Conditioned media collected from COS-7 cells transiently transfected with soluble TbRIII inhibited the ability of A549-Neo cells to invade Matrigel by 16 ± 6% (P 5 0.03, two-tailed t-test). Although A549-RIII cells were inhibited by 24 ± 8% in their invasion compared with A549-Neo cells (P 5 0.02, two-tailed t-test), the addition of sTbRIII to A549-RIII cells further inhibited their ability to invade Matrigel with 43 ± 6.1% inhibition (P , 0.001, two-tailed t-test) ( Figure 5E ). These results demonstrate that TbRIII inhibits cell invasion, at least in part, through generation of sTbRIII. Taken together, these results suggest that one consequence of loss of TbRIII expression in NSCLC is increased cellular motility and invasiveness due to decreased sTbRIII production.
TbRIII inhibits anchorage-independent growth in soft agar
The ability of TbRIII to decrease lung cancer cell motility and invasiveness in vitro suggested that TbRIII may have effects on lung cancer tumorigenicity. We examined anchorage-independent growth using colony formation in soft agar. Since A549 cells only form small and difficult to quantitate colonies using this assay, we concentrated on the H460 cell model. Stable cell lines expressing the empty vector pcDNA3.1 or TbRIII were seeded in 0.4% agar on a 0.71% base agar and incubated for 7-14 days after which colony formation was assessed. TbRIII significantly decreased colony formation with H460-RIII cells forming an average of 50.4 ± 2.3% less colonies than H460-Neo cells ( Figure 5F , P , 0.0001, two-tailed t-test). These studies suggest that loss of TbRIII expression during lung progression not only increases lung cancer cell motility and invasiveness but also facilitates anchorage-independent growth, a hallmark of tumorigenesis.
TbRIII inhibits tumorigenicity in vivo
To examine whether the effects of TbRIII on migration, invasion and tumorigenicity in vitro translated to effects on tumorigenicity in vivo, we injected A549 cells stably expressing TbRIII or an empty vector control into both flanks of female Balb/c Nu/Nu mice and measured TbRIII suppresses lung cancer invasiveness tumor volume every 3 days. There was a noticeable difference in tumor incidence, with 100% (12/12) of the injection sites developing tumors in the A549-Neo group, whereas in the A549-RIII group, only 71% (10/14) of the injection sites formed tumors ( Figure 6A ). In addition, tumor volume was calculated over the time course with A549-Neo mice consistently demonstrating a higher average tumor volume than A549-RIII mice ( Figure 6B , P 5 0.001, analysis of variance). Primary tumors and potential distant metastasis were extracted, Hematoxylin & Eosin (H&E) stained and analyzed by a board certified pathologist. Whereas all of the A549-Neo tumor sections containing skeletal muscle demonstrated invasion into muscle, only 70% of the A549-RIII tumors exhibited unambiguous skeletal muscle invasion. A549 cells have been reported to have a very low pulmonary metastasis rate ($0.4%), with this being the most common site of metastasis (33) . After examination of possible lung metastatic lesions by H&E staining, a lung metastasis in one of the A549-Neo mice was confirmed, whereas none of the A549-RIII mice exhibited lung metastasis. These studies support TbRIII as a novel tumor suppressor in NSCLC.
Discussion
Lung cancer is the leading cause of cancer death in both males and females in the USA, with more people dying from lung cancer than from breast, colon and prostate cancer combined (34) . In 2006, there will be 174 470 new cases and 162 460 deaths in the US, with more than 1 000 000 people dying from lung cancer worldwide. The 5-year survival rate for lung cancer is 15%, as compared with 88% for breast cancer and 99% for prostate cancer, underscore the importance of defining mechanisms facilitating lung cancer progression.
Here we have characterized a TGF-b superfamily co-receptor, TbRIII, as a novel tumor suppressor gene in NSCLC. Data to support TbRIII as a tumor suppressor include frequent loss of TbRIII expression at the message and protein levels, with LOH of the TGFBR3 locus correlating with loss of expression, and decreased TbRIII expression correlating with disease progression and a higher grade/less differentiated tumor. Importantly, restoring TbRIII expression decreased migration, invasion and anchorage-independent growth in vitro and tumorigenicity in vivo, while further decreasing TbRIII expression enhanced invasiveness, suggesting important functional roles for loss of TbRIII expression during lung cancer progression.
Loss of expression of tumor suppressor genes is usually multifactorial, with mechanisms including chromosomal alterations/deletions resulting in LOH, mutation, transcriptional and epigenetic regulation (26, 35) . Although LOH occurred in 38.5% of specimens and correlated with decreased expression in those specimens, consistent with prior reports demonstrating LOH in 60% (38/63) of lung tumor samples at chromosome 1p where the TGFBR3 gene is located, clearly other mechanisms must be involved since all tumor-matched normal pairs demonstrated TbRIII loss at the protein level. In addition, the samples that demonstrated LOH were all squamous cell carcinomas, suggesting that LOH may be a preferential mechanism for TbRIII loss in this subtype of NSCLC. Examination of the TGFBR3 gene promoter reveals several CpG islands and TbRIII expression appears to be epigenetically regulated in prostate (20) and ovarian cancer (36) . Whether transcriptional or epigenetic regulation are involved in decreasing TbRIII expression in NSCLC is currently being explored.
Although TbRIII has a clear role in decreasing lung cancer cell migration, invasion and anchorage-independent growth, and these effects appear to be mediated, in part, through generation of sTbRIII, how TbRIII and sTbRIII mediate these effects remains unclear. TbRIII could be functioning as a co-receptor, resulting in increased TGF-b binding and canonical Smad-dependent TGF-b signaling (37) . On the other hand, TbRIII could be functioning through its interacting partners, b-arrestin2 and GIPC, both of which are expressed in the lung (38) , to signal to Smad-independent pathways (14, 39, 40) . Alternatively, generation of sTbRIII could abrogate some of the functions of cell-surface TbRIII, or directly function to sequester TGF-b and downregulate TGF-b signaling (41) . Indeed, previous studies in both breast and prostate cancer xenograft models reported a role for both full-length TbRIII and soluble TbRIII in decreasing tumor growth, metastasis and angiogenesis (27, 42, 43) . In addition, although TbRIII had no effect on proliferation in vitro, enhanced growth in soft agar and in vivo could reflect effects on increased lung cancer cell survival. Whether TbRIII functions to regulate lung cancer cell migration, invasion, anchorage-independent growth or survival by signaling through Smad-dependent or Smad-independent pathways remains an active area of investigation.
Most studies examining lung cancer are performed in NSCLC models, as this type accounts for .80% of all lung cancers (34) . However, there are fundamental differences between NSCLC and small cell lung cancers, including their clinical behavior and natural history, their response to therapy and their potential cells of origin. There are also differences in terms of TGF-b signaling, with loss of TbRII expression more common in small cell lung cancer (19) , as well as a report that small cell lung cancer cell lines do not synthesize TGF-b1 or TGF-b2 (44) . Whether TbRIII expression is lost in human small cell lung cancer patients remains to be established.
The main reasons for the high mortality rate in lung cancer patients are that lung cancer is usually diagnosed in the advanced stages and the lack of effective treatments for lung cancer. As loss of TbRIII expression correlates with lung cancer progression, investigation of the role of TbRIII could lead to advances in both the diagnosis and treatment of lung cancer. As LOH of the TGFBR3 gene locus does not fully account for decreased TbRIII expression in lung cancer, and TbRIII could be subject to epigenetic regulation, TbRIII expression could be restored with HDAC inhibitors or 5-azacytidine analogs currently in clinical use or being evaluated in clinical trials. In addition, as TbRIII expression correlates with disease expression and differentiation status, TbRIII expression levels could have prognostic value in NSCLC. Whether analysis of TbRIII expression in lung cancer biopsies could provide useful information to treating physicians warrants further investigation.
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Supplementary Figures 1A-C, 2A-C and 3A and 3B and colour version of Figure 3 can be found at http://carcin.oxfordjournals.org/.
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